*Address correspondence to Steven G. Morgan, Ph.D., Assistant Professor, Centre for Health Services and Policy Research, University of British Columbia, 429-2194 Health Sciences Mall, Vancouver, BC, Canada V6T 1Z3.
Prescription Drug Expenditures and Population Demographics
Article first published online: 4 JAN 2006
Health Services Research
Volume 41, Issue 2, pages 411–428, April 2006
How to Cite
Morgan, S. G. (2006), Prescription Drug Expenditures and Population Demographics. Health Services Research, 41: 411–428. doi: 10.1111/j.1475-6773.2005.00495.x
- Issue published online: 4 JAN 2006
- Article first published online: 4 JAN 2006
- Prescription drugs;
- British Columbia
Objective. To provide detailed demographic profiles of prescription drug utilization and expenditures in order to isolate the impact of demographic change from other factors that affect drug expenditure trends.
Data Sources/Study Setting. Demographic information and drug utilization data were extracted for virtually the entire British Columbia (BC) population of 1996 and 2002. All residents had public medical and hospital insurance; however their drug coverage resembled the mix of private and public insurance in the United States.
Study Design. A series of research variables were constructed to illustrate profiles of drug expenditures and drug utilization across 96 age/sex strata.
Data Collection/Extraction Methods. Drug use and expenditure information was extracted from the BC PharmaNet, a computer network connecting all pharmacies in the province.
Principal Findings. Per capita drug expenditures increased at an average annual rate of 10.8 percent between 1996 and 2002. Population aging explained 1.0 points of this annual rate of expenditure growth; the balance was attributable to rising age/sex-specific drug expenditures.
Conclusions. Relatively little of the observed increase in drug expenditures in BC could be attributed to demographic change. Most of the expenditure increase stemmed from the age/sex-specific quantity and type of drugs purchased. The sustainability of drug spending therefore depends not on outside forces but on decisions made by policy makers, prescribers, and patients.